Literature DB >> 29693493

Targeted next-generation sequencing reveals that a compound heterozygous mutation in phosphodiesterase 6a gene leads to retinitis pigmentosa in a Chinese family.

Shanshan Zhang1, Jie Li2, Shujin Li3, Yeming Yang1, Mu Yang3, Zhenglin Yang1,2,3,4, Xianjun Zhu1,2,3,4, Lin Zhang1,2,4.   

Abstract

PURPOSE: Retinitis pigmentosa (RP) is a genetically heterogeneous disease with over 70 causative genes identified to date. However, approximately 40% of RP cases remain genetically unsolved, suggesting that many novel disease-causing mutations are yet to be identified. The purpose of this study is to identify the causative mutations of a Chinese RP family.
METHODS: Targeted next-generation sequencing (NGS) for a total of 163 genes which involved in inherited retinal disorders were used to screen the possible causative mutations. Sanger sequencing was used to verify the mutations.
RESULTS: As results, we identified two heterozygous mutations: a splicing site mutation c.1407 + 1G>C and a nonsense mutation c. 1957C>T (p.R653X) in phosphodiesterase 6A (PDE6A) gene in the RP patient. These two mutations are inherited from his father and mother, respectively. Furthermore, these mutations are unique in our in-house database and are rare in human genome databases, implicating that these two mutations are pathological.
CONCLUSION: By using targeted NGS method, we identified a compound heterozygous mutation in PDE6A gene that is associated with RP in a Chinese family.

Entities:  

Keywords:  NGS; PDE6A mutation; Retinitis pigmentosa

Mesh:

Substances:

Year:  2018        PMID: 29693493     DOI: 10.1080/13816810.2018.1461912

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  1 in total

1.  Novel variants in PDE6A and PDE6B genes and its phenotypes in patients with retinitis pigmentosa in Chinese families.

Authors:  Yuyu Li; Ruyi Li; Hehua Dai; Genlin Li
Journal:  BMC Ophthalmol       Date:  2022-01-15       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.